Early initiation of dual antiplatelet therapy may provide substantial protective benefits for patients undergoing percutaneous coronary intervention. A large registry analysis presented at the European Society of Cardiology Congress 2025 examined 53,898 PCI procedures from the “France PCI” registry between 2014 and 2020.

Patients were divided into those receiving pretreatment (83.2%) versus no pretreatment (16.8%). In-hospital stent thrombosis occurred in 0.1% of the pretreatment group compared with 0.4% in the no-pretreatment group, highlighting a significant protective effect (odds ratio: 0.35, 95% CI: 0.22–0.57). At one year, the pretreatment group also had reduced rates of major adverse cardiovascular events (6.6% vs. 7.8%) and all-cause mortality (4.6% vs. 6.0%). Importantly, these benefits were achieved without a significant increase in major bleeding events.

This study reinforces the potential advantage of DAPT pretreatment in patients undergoing PCI for chronic coronary syndrome and non-ST-segment elevation myocardial infarction, suggesting that early antiplatelet therapy can improve both short-term and long-term outcomes in real-world clinical practice.